Modulation of nitric oxide synthases by betaines

• US 8,318,805 B2
• Filed: 05/10/2007
• Issued: 11/27/2012
• Est. Priority Date: 11/10/2004
• Status: Expired due to Fees

• Current Assignee: Jallal Messadek
• Original Assignee: Jallal Messadek
• Inventors: Messadek, Jallal
• Primary Examiner(s): Gamett, Daniel C
• Application Number:
  US11/747,167
• Publication Number:
  US 20070213399A1
• Time in Patent Office: 2,028 Days
• Field of Search: None
• US Class Current: 514/556
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to therapeutic compositions of betaines and L-arginine and physiologically acceptable salts thereof, and to pharmaceutical uses of betaines for up-regulating, enhancing, stimulating, controlling and/or increasing constitutive nitric oxide synthase expression a mammal, particularly in a human. Additionally, the betaines are believed to augment after administration both immunological and functional (activity) expression of Tissue Factor Pathway Inhibitor (TFPI) in a mammal, particularly a human.

Claims

1. A method for treating a patient suffering from a condition related to constitutive nitric oxide deficiency, wherein said condition is pulmonary hypertension, said method comprising the step of administering to the patient an efficient therapeutical amount of betaine for increasing in said patient at least one nitric oxide production pathway selected from the group consisting of constitutive nitric oxide synthase expression, constitutive Endothelial nitric oxide synthase expression, eNOS nitric oxide synthase expression, neural NOS nitric oxide synthase expression (nNOS), platelet NOS nitric oxide synthase expression, cNOS nitric oxide synthase expression, Type III nitric oxide synthase expressions, calcium dependant nitric oxide synthase expression, calcium dependant nitric oxide synthase production, endogenous nitric oxide production, and combinations thereof, said betaine being administered orally in an oral composition comprising at least (a) 20% by weight betaine and (b) 20% by weight L-arginine or a physiologically acceptable salt thereof.

2. The method of claim 1, in which the patient is administered with an efficient therapeutical amount of glycine betaine for increasing the rate of said at least one nitric oxide production pathway in said patient.

3. The method of claim 1, in which the patient is administered with an efficient therapeutical amount of glycine betaine for increasing by a factor comprised between 1.2 and 3 the rate of said at least one nitric oxide production in said patient.

4. The method of claim 1, in which the weight ratio L-arginine or salt thereof/betaine is comprised between 0.5 and 2.

5. The method of claim 1 for treating a patient suffering from a condition related to deficiency of nitric oxide, wherein said condition is pulmonary hypertension, in which the patient is administered with an efficient therapeutical amount of betaine for increasing bioavailability of endothelial nitric oxide in a mammal.

6. The method of claim 1 for treating a patient suffering from a condition related to deficiency of nitric oxide, wherein said condition is pulmonary hypertension, in which the patient is administered with an efficient therapeutical amount of betaine for controlling and/or up-regulating endothelial nitric oxide bioavailability in a mammal.

7. The method of claim 1 for treating a patient suffering from a condition related to deficiency of nitric oxide, wherein said condition is pulmonary hypertension, in which the patient is administered with an efficient therapeutical amount of betaine for controlling and/or up-regulating endogenous nitric oxide synthase expression in a mammal.

8. The method of claim 1, in which the patient is further administered a therapeutical effective amount of at least one compound selected from the group consisting of nifepidine, arginine analogues, stimulators of NO release, carbachol, acetylcholine, bradykinin and combinations thereof.

9. The method of claim 1, in which the patient is further administered a therapeutical effective amount of at least one compound selected from the group consisting of statins, probucol, antioxidant vitamins, eNOS substrate, cofactors thereof, tetrahydrobiopterin, and combinations thereof.

10. The method of claim 1, in which the patient is further administered an effective amount of at least one active agent selected from the group consisting of natural antioxidants, vitamins C, ascorbic acid, vitamins E, tocopherol isomers, a-tocopherol, tocotrienols, vitamin E isomers, probucol, ascorbate, phytochemicals, flavonoids, isoflavones, polyphenols, anthocyans, and combinations thereof.

11. The method of claim 1, in which the patient is further administered a therapeutical effective amount of bosentan.

12. A method for treating a patient suffering from a condition related to excess endothelin-1 (ET-1), in which the patient is administered with an efficient therapeutical amount of betaine for lowering endothelin-1 (ET-1) levels in said patient, wherein said condition is pulmonary hypertension.

13. The method of claim 12, in which the patient is administered with an efficient therapeutical amount of glycine betaine for decreasing the rate of endothelin-1 (ET-1) expression in said patient.

14. The method of claim 12, in which the patient is administered with an efficient therapeutical amount of glycine betaine for decreasing by a factor of between 1.2 and 5 the rate of endothelin-1 (ET-1) expression in said patient.

15. The method of claim 12, in which the patient is further administered a therapeutical effective amount of bosentan.

16. The method of claim 12, in which a clinical marker for pulmonary hypertension is improved in the patient, said clinical marker being selected from the group consisting of pulmonary arterial pressure, heart rhythm, 6 minute walking test performance on a treadmill, quality of life, and survival.

17. A method for treating a patient suffering from a condition related to endothelial cells, in which said patient is administered an efficient therapeutical amount of betaine for improving endothelial cell function through activation of eNOS and through protection of the endothelium from oxidative stress, wherein said condition is pulmonary hypertension.

18. The method of claim 17, in which the patient is further administered a therapeutical effective amount of bosentan.

19. A method for treating a patient suffering from a condition related to lack of activated eNOS, in which said patient is administered an efficient therapeutical amount of betaine to destabilize the complex between eNOS and caveolin for activating eNOS, wherein said condition is pulmonary hypertension.

20. The method of claim 19, in which the patient is further administered a therapeutical effective amount of bosentan.

21. A method for increasing constitutive Nitric Oxide Synthase activity in a subject to treat a condition favorably affected by an increase in constitutive Nitric Oxide levels in a cell, a tissue, an organ, a bodily fluid, blood, comprising:

administering to a subject in need of such treatment an effective amount of a betaine; and

co-administering a substrate of Nitric Oxide Synthase, wherein said condition is pulmonary hypertension.

22. The method of claim 21, in which the patient is further administered a therapeutical effective amount of bosentan.